{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T22:49:40Z","timestamp":1773269380739,"version":"3.50.1"},"reference-count":58,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Human induced pluripotent stem cell (iPSC) and CRISPR-Cas9 gene-editing technologies have become powerful tools in disease modeling and treatment. By harnessing recent biotechnological advancements, this review aims to equip researchers and clinicians with a comprehensive and updated understanding of the evolving treatment landscape for metabolic and genetic disorders, highlighting how iPSCs provide a unique platform for detailed pathological modeling and pharmacological testing, driving forward precision medicine and drug discovery. Concurrently, CRISPR-Cas9 offers unprecedented precision in gene correction, presenting potential curative therapies that move beyond symptomatic treatment. Therefore, this review examines the transformative role of iPSC technology and CRISPR-Cas9 gene editing in addressing metabolic and genetic disorders such as alpha-1 antitrypsin deficiency (A1AD) and glycogen storage disease (GSD), which significantly impact liver and pulmonary health and pose substantial challenges in clinical management. In addition, this review discusses significant achievements alongside persistent challenges such as technical limitations, ethical concerns, and regulatory hurdles. Future directions, including innovations in gene-editing accuracy and therapeutic delivery systems, are emphasized for next-generation therapies that leverage the full potential of iPSC and CRISPR-Cas9 technologies.<\/jats:p>","DOI":"10.3390\/cells13121052","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T07:33:20Z","timestamp":1718696000000},"page":"1052","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Induced Pluripotent Stem Cells and CRISPR-Cas9 Innovations for Treating Alpha-1 Antitrypsin Deficiency and Glycogen Storage Diseases"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4957-1811","authenticated-orcid":false,"given":"Colin","family":"Walsh","sequence":"first","affiliation":[{"name":"Department of Biomedical Engineering, Thomas J. Watson College of Engineering and Applied Sciences, State University of New York at Binghamton, Binghamton, NY 13902, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8033-8110","authenticated-orcid":false,"given":"Sha","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Thomas J. Watson College of Engineering and Applied Sciences, State University of New York at Binghamton, Binghamton, NY 13902, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.drudis.2018.10.001","article-title":"Implications of human induced pluripotent stem cells in metabolic disorders: From drug discovery toward precision medicine","volume":"24","year":"2019","journal-title":"Drug Discov. Today"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s11154-021-09671-z","article-title":"Inborn errors of metabolism: Lessons from iPSC models","volume":"22","author":"Raya","year":"2021","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Lopes, C., Tang, Y., Anjo, S.I., Manadas, B., Onofre, I., de Almeida, L.P., Daley, G.Q., Schlaeger, T.M., and Rego, A.C.C. (2020). Mitochondrial and redox modifications in huntington disease induced pluripotent stem cells rescued by CRISPR\/Cas9 CAGs targeting. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.576592"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"100863","DOI":"10.1016\/j.ymgmr.2022.100863","article-title":"CRISPR correction of the Finnish ornithine delta-aminotransferase mutation restores metabolic homeostasis in iPSC from patients with gyrate atrophy","volume":"31","author":"Maldonado","year":"2022","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Song, H.-Y., Yang, Y.-P., Chien, Y., Lai, W.-Y., Lin, Y.-Y., Chou, S.-J., Wang, M.-L., Wang, C.-Y., Leu, H.-B., and Yu, W.-C. (2021). Reversal of the inflammatory responses in Fabry patient IPSC-derived cardiovascular endothelial cells by CRISPR\/Cas9-corrected mutation. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22052381"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41392-023-01309-7","article-title":"CRISPR\/Cas9 therapeutics: Progress and prospects","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_7","first-page":"65","article-title":"Overview of alpha-1 antitrypsin deficiency-mediated liver disease","volume":"7","author":"Karatas","year":"2019","journal-title":"Eur. Med. J."},{"key":"ref_8","first-page":"172","article-title":"Alpha-1 antitrypsin deficiency-mediated liver toxicity: Why do some patients do poorly? What do we know so far?","volume":"7","author":"Bouchecareilh","year":"2020","journal-title":"Chronic Obstr. Pulm. Dis. J. COPD Found."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1093\/hmg\/ddz133","article-title":"Gene therapy for glycogen storage diseases","volume":"28","author":"Kishnani","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Adlat, S., Salgado, A.M.V., Lee, M., Yin, D., and Wangensteen, K.J. (Hepatology, 2023). Emerging and potential use of CRISPR in human liver disease, Hepatology, Online ahead of print.","DOI":"10.1097\/HEP.0000000000000578"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3389\/fmed.2019.00265","article-title":"iPSC-derived hepatocytes as a platform for disease modeling and drug discovery","volume":"6","author":"Corbett","year":"2019","journal-title":"Front. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/hep.30288","article-title":"The use of human pluripotent stem cells for modeling liver development and disease","volume":"69","author":"Heslop","year":"2019","journal-title":"Hepatology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41576-019-0100-z","article-title":"Induced pluripotent stem cells in disease modelling and drug discovery","volume":"20","author":"Rowe","year":"2019","journal-title":"Nat. Rev. Genet."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Yefroyev, D.A., and Jin, S. (2022). Induced pluripotent stem cells for treatment of Alzheimer\u2019s and Parkinson\u2019s diseases. Biomedicines, 10.","DOI":"10.3390\/biomedicines10020208"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Ogi, D.A., and Jin, S. (2023). Transcriptome-Powered Pluripotent Stem Cell Differentiation for Regenerative Medicine. Cells, 12.","DOI":"10.3390\/cells12101442"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Blaszkiewicz, J., and Duncan, S.A. (2022). Advancements in disease modeling and drug discovery using iPSC-derived hepatocyte-like cells. Genes, 13.","DOI":"10.3390\/genes13040573"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Caiazza, C., Parisi, S., and Caiazzo, M. (2021). Liver organoids: Updates on disease modeling and biomedical applications. Biology, 10.","DOI":"10.3390\/biology10090835"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.3748\/wjg.v29.i25.3932","article-title":"Glycogen storage diseases: An update","volume":"29","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"103214","DOI":"10.1016\/j.scr.2023.103214","article-title":"Generation of three induced pluripotent stem cell lines from patients with glycogen storage disease type III","volume":"72","author":"Rossiaud","year":"2023","journal-title":"Stem Cell Res."},{"key":"ref_20","first-page":"2","article-title":"Modeling Liver Diseases Using Induced Pluripotent Stem Cell (iPSC)-Derived Hepatocytes","volume":"4","author":"Contreras","year":"2014","journal-title":"J. Stem Cell Res. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nrm.2016.8","article-title":"A decade of transcription factor-mediated reprogramming to pluripotency","volume":"17","author":"Takahashi","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1126\/science.1239278","article-title":"Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds","volume":"341","author":"Hou","year":"2013","journal-title":"Science"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nature12587","article-title":"Deterministic direct reprogramming of somatic cells to pluripotency","volume":"502","author":"Rais","year":"2013","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.stem.2008.05.011","article-title":"A combined chemical and genetic approach for the generation of induced pluripotent stem cells","volume":"2","author":"Shi","year":"2008","journal-title":"Cell Stem Cell"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Li, C., Wang, L., Cseke, L.J., Vasconcelos, F., Huguet-Tapia, J.C., Gassmann, W., Pauwels, L., White, F.F., Dong, H., and Yang, B. (2023). Efficient CRISPR-Cas9 based cytosine base editors for phytopathogenic bacteria. Commun. Biol., 6.","DOI":"10.1038\/s42003-023-04451-8"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of A\u2022 T to G\u2022 C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1016\/j.ymthe.2021.06.021","article-title":"Adenine base editing reduces misfolded protein accumulation and toxicity in alpha-1 antitrypsin deficient patient iPSC-hepatocytes","volume":"29","author":"Werder","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/hep.27753","article-title":"Induced pluripotent stem cells model personalized variations in liver disease resulting from \u03b11-antitrypsin deficiency","volume":"62","author":"Tafaleng","year":"2015","journal-title":"Hepatology"},{"key":"ref_29","first-page":"258","article-title":"Patient-derived induced pluripotent stem cells for alpha-1 antitrypsin deficiency disease modeling and therapeutic discovery","volume":"5","author":"Kaserman","year":"2018","journal-title":"Chronic Obstr. Pulm. Dis. J. COPD Found."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.stemcr.2015.02.021","article-title":"Emergence of a stage-dependent human liver disease signature with directed differentiation of alpha-1 antitrypsin-deficient iPS cells","volume":"4","author":"Wilson","year":"2015","journal-title":"Stem Cell Rep."},{"key":"ref_31","first-page":"76","article-title":"Disease modeling using human induced pluripotent stem cells: Lessons from the liver","volume":"1851","author":"Colquhoun","year":"2015","journal-title":"Biochim. Biophys. Acta (BBA) Mol. Cell Biol. Lipids"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"102095","DOI":"10.1016\/j.scr.2020.102095","article-title":"Generation of a human induced pluripotent stem cell line, BRCi009-A, derived from a patient with glycogen storage disease type 1a","volume":"49","author":"Katagami","year":"2020","journal-title":"Stem Cell Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/gtc.12101","article-title":"Establishment and directed differentiation of induced pluripotent stem cells from glycogen storage disease type I b patient","volume":"18","author":"Satoh","year":"2013","journal-title":"Genes Cells"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Rossiaud, L., Fragner, P., Barbon, E., Gardin, A., Benabides, M., Pellier, E., Cosette, J., El Kassar, L., Giraud-Triboult, K., and Nissan, X. (2023). Pathological modeling of glycogen storage disease type III with CRISPR\/Cas9 edited human pluripotent stem cells. Front. Cell Dev. Biol., 11.","DOI":"10.3389\/fcell.2023.1163427"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"101069","DOI":"10.1016\/j.ymgmr.2024.101069","article-title":"Induced pluripotent stem cell (iPSC) modeling validates reduced GBE1 enzyme activity due to a novel variant, p. Ile694Asn, found in a patient with suspected glycogen storage disease IV","volume":"39","author":"Naito","year":"2024","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/jimd.12654","article-title":"Gene therapy for glycogen storage diseases","volume":"47","author":"Koeberl","year":"2024","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"23","DOI":"10.21037\/tgh.2019.10.10","article-title":"Genome editing technologies to treat rare liver diseases","volume":"5","author":"Trevisan","year":"2020","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/j.ymthe.2020.12.027","article-title":"Correction of metabolic abnormalities in a mouse model of glycogen storage disease type Ia by CRISPR\/Cas9-based gene editing","volume":"29","author":"Arnaoutova","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1167091","DOI":"10.3389\/fmmed.2023.1167091","article-title":"Gene therapy and genome editing for type I glycogen storage diseases","volume":"3","author":"Chou","year":"2023","journal-title":"Front. Mol. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2016.02.025","article-title":"The potential of induced pluripotent stem cell derived hepatocytes","volume":"65","author":"Hannoun","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"100198","DOI":"10.1016\/j.jhepr.2020.100198","article-title":"Organoids to model liver disease","volume":"3","author":"Nuciforo","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"20406223211014025","DOI":"10.1177\/20406223211014025","article-title":"Alpha-1 antitrypsin deficiency research and emerging treatment strategies: What\u2019s down the road?","volume":"12","author":"Rahaghi","year":"2021","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1208\/s12248-021-00608-7","article-title":"Non-viral vectors in gene therapy: Recent development, challenges, and prospects","volume":"23","author":"Zu","year":"2021","journal-title":"AAPS J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41586-020-1978-5","article-title":"The promise and challenge of therapeutic genome editing","volume":"578","author":"Doudna","year":"2020","journal-title":"Nature"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA\u2013guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.ymthe.2022.01.040","article-title":"Evaluation of cytosine base editing and adenine base editing as a potential treatment for alpha-1 antitrypsin deficiency","volume":"30","author":"Packer","year":"2022","journal-title":"Mol. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2147\/TACG.S257511","article-title":"Known mutations at the cause of alpha-1 antitrypsin deficiency an updated overview of SERPINA1 variation spectrum","volume":"14","author":"Seixas","year":"2021","journal-title":"Appl. Clin. Genet."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/mt.2014.226","article-title":"Efficient and allele-specific genome editing of disease loci in human iPSCs","volume":"23","author":"Smith","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.gene.2019.04.002","article-title":"CRISPR\/Cas9 genome editing of SLC37A4 gene elucidates the role of molecular markers of endoplasmic reticulum stress and apoptosis in renal involvement in glycogen storage disease type Ib","volume":"703","author":"Skakic","year":"2019","journal-title":"Gene"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1002\/hep.32022","article-title":"Modeling Phenotypic Heterogeneity of Glycogen Storage Disease Type 1a Liver Disease in Mice by Somatic CRISPR\/CRISPR-associated protein 9\u2013Mediated Gene Editing","volume":"74","author":"Rutten","year":"2021","journal-title":"Hepatology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3389\/fonc.2019.00297","article-title":"Gene therapy leaves a vicious cycle","volume":"9","author":"Goswami","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Doss, M., and Sachinidis, A. Current challenges of iPSC-based disease modeling and therapeutic implications. Cells 8: 403. 2019.","DOI":"10.3390\/cells8050403"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Reshetnikov, V.V., Chirinskaite, A.V., Sopova, J.V., Ivanov, R.A., and Leonova, E.I. (2022). Translational potential of base-editing tools for gene therapy of monogenic diseases. Front. Bioeng. Biotechnol., 10.","DOI":"10.3389\/fbioe.2022.942440"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3389\/fgene.2019.00868","article-title":"Development and clinical translation of approved gene therapy products for genetic disorders","volume":"10","author":"Shahryari","year":"2019","journal-title":"Front. Genet."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.gendis.2023.02.027","article-title":"Clinical applications of the CRISPR\/Cas9 genome-editing system: Delivery options and challenges in precision medicine","volume":"11","author":"Khoshandam","year":"2024","journal-title":"Genes Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"dmm049874","DOI":"10.1242\/dmm.049874","article-title":"New advances in CRISPR\/Cas-mediated precise gene-editing techniques","volume":"16","author":"Richardson","year":"2023","journal-title":"Dis. Models Mech."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Tyumentseva, M., Tyumentsev, A., and Akimkin, V. (2023). CRISPR\/Cas9 landscape: Current state and future perspectives. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242216077"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Xu, Z., Yang, J., Xin, X., Liu, C., Li, L., Mei, X., and Li, M. (2023). Merits and challenges of iPSC-derived organoids for clinical applications. Front. Cell Dev. Biol., 11.","DOI":"10.3389\/fcell.2023.1188905"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/12\/1052\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:00:23Z","timestamp":1760108423000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/12\/1052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,18]]},"references-count":58,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["cells13121052"],"URL":"https:\/\/doi.org\/10.3390\/cells13121052","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,18]]}}}